Ketamine Tablet: Complete Overview

Ketamine tablet represents one of the most accessible and increasingly utilized forms of ketamine therapy available today. While the drug has been used intravenously for decades in clinical settings, oral formulations have opened up treatment options for patients who cannot access infusion clinics or who require maintenance therapy between IV treatments.

What Is Ketamine Tablet?

Ketamine is a dissociative anesthetic originally developed in the 1960s and approved by the FDA for anesthetic use in 1970. Since then, its applications have expanded dramatically. When taken orally, ketamine is absorbed through the gastrointestinal tract and metabolized by the liver before entering systemic circulation — a process that significantly affects how much of the drug ultimately reaches the brain and bloodstream.

Ketamine tablet is prescribed off-label for a growing list of psychiatric and pain conditions, most notably treatment-resistant depression, anxiety disorders, PTSD, and chronic pain syndromes.

Forms Available

Ketamine tablet comes in several distinct formulations, each with different absorption characteristics and clinical applications:

Tablets

Pharmaceutical-grade ketamine tablets are compounded or manufactured in fixed doses. They are swallowed whole, passing through the digestive system before absorption. Tablets provide consistent dosing and are easy to store and administer.

Troches (Buccal Lozenges)

Troches are designed to dissolve slowly in the mouth, allowing some absorption through the buccal mucosa (the lining of the cheeks and gums). This partially bypasses first-pass metabolism in the liver, resulting in slightly higher bioavailability than swallowed tablets. For a detailed comparison of these forms, see our article on tablet vs. troche vs. lozenge.

Oral Solutions

Liquid ketamine can be prepared by compounding pharmacies and taken orally. Solutions allow for flexible dosing adjustments but require careful measurement.

Capsules

Capsules filled with ketamine powder are another compounded option. Like tablets, they are swallowed and subject to full first-pass hepatic metabolism.

Bioavailability: The Core Challenge

One of the defining characteristics of ketamine tablet — and the factor that most distinguishes it from IV therapy — is its low bioavailability. When ketamine is taken orally, only 10 to 25 percent of the administered dose typically reaches systemic circulation.

This stands in stark contrast to intravenous ketamine, which achieves nearly 100 percent bioavailability, or intramuscular ketamine at 90 to 95 percent. Even sublingual and intranasal routes achieve higher bioavailability (25 to 50 percent and 25 to 50 percent respectively) than straight oral ingestion.

The consequence is that oral doses must be significantly higher than IV doses to achieve comparable plasma levels. A patient receiving 0.5 mg/kg IV might need 3 to 6 mg/kg orally to approximate similar effects — though oral therapy is often managed at lower doses targeting different therapeutic mechanisms.

Why Low Bioavailability Isn't Necessarily a Problem

The low bioavailability of ketamine tablet actually confers some clinical advantages:

• Lower dissociative burden: Patients typically experience less intense dissociative or psychedelic effects at oral therapeutic doses
• Outpatient suitability: The milder experience allows some patients to take doses at home with appropriate supervision
• Norketamine accumulation: First-pass metabolism generates substantial amounts of norketamine, an active metabolite that may contribute to antidepressant and analgesic effects

Clinical History

Ketamine tablet's clinical use traces back to the 1990s when pain specialists began experimenting with it for chronic pain management. Palliative care practitioners were among the earliest adopters, using ketamine tablet to manage refractory cancer pain when intravenous access was impractical.

In the early 2000s, as research on ketamine's rapid antidepressant effects began accumulating, psychiatrists started exploring oral formulations for depression. The advantage was clear: oral administration at home could potentially maintain the antidepressant response achieved during IV treatment.

Current Clinical Uses

Today, ketamine tablet is used across several clinical domains:

Psychiatric Applications

• Treatment-resistant depression (TRD): Patients who have failed multiple antidepressant trials may respond to ketamine tablet, particularly as maintenance therapy
• Anxiety disorders: Generalized anxiety disorder, social anxiety, and panic disorder are being investigated
• PTSD: Some protocols use ketamine tablet as part of broader trauma treatment programs
• OCD: Preliminary research suggests glutamate modulation may benefit some OCD patients

Pain Applications

• Chronic regional pain syndrome (CRPS): Low-dose ketamine tablet may reduce central sensitization
• Neuropathic pain: Diabetic neuropathy, postherpetic neuralgia, and other neuropathic conditions
• Fibromyalgia: Some patients report benefit from low chronic doses
• Palliative/cancer pain: Ketamine tablet remains used for refractory pain in terminal illness

Perioperative Use

Some surgical centers use ketamine tablet preoperatively to reduce anxiety and opioid requirements postoperatively.

Regulatory Status

Ketamine itself is FDA-approved as an anesthetic (Ketalar). All psychiatric and pain uses of ketamine tablet are off-label, meaning the FDA has not specifically approved these applications. However, off-label prescribing is legal and common in medicine.

Ketamine tablet is primarily accessed through:

1. Compounding pharmacies under physician prescription
2. Some 503B outsourcing facilities that produce larger batches under stricter oversight

The FDA classifies ketamine as a Schedule III controlled substance, meaning prescribers must follow DEA requirements for controlled substance prescribing.

Safety Considerations

Ketamine tablet is generally well-tolerated at therapeutic doses, but carries risks that require appropriate screening and monitoring:

• Dissociation and cognitive effects: Even at lower oral doses, some patients experience perceptual changes
• Cardiovascular effects: Transient increases in blood pressure and heart rate
• Bladder toxicity: With chronic high-dose use, ketamine can cause serious urinary tract damage — a concern primarily at recreational doses but worth monitoring clinically
• Dependence potential: As a Schedule III substance, abuse potential exists and requires appropriate patient selection

The Role of Ketamine Tablet Today

Ketamine tablet occupies a unique niche in the treatment landscape. It is less powerful than IV infusion in terms of acute effect, but more accessible, more affordable, and more practical for long-term maintenance. As compounding regulations evolve and more research accumulates, oral formulations are likely to become a more formalized part of psychiatric and pain treatment protocols.

For patients and clinicians alike, understanding the pharmacology, formulations, and appropriate clinical use of ketamine tablet is increasingly important as this treatment option becomes more widely discussed and prescribed.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches